Literature DB >> 2666593

The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

C M Carapella1, M G Paggi, F Cattani, G B Ciottoli, A Floridi, B Iandolo, L Raus, A Riccio, A Caputo.   

Abstract

Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2666593     DOI： 10.1007/bf00149384

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  Combined modality treatment of malignant glioma.

Authors:  W R Shapiro
Journal:  Prog Exp Tumor Res       Date:  1985

2.  Treatment of adult malignant gliomas.

Authors:  P Pouillart; T Palangie; M Poisson; A Buge; P Huguenin; P Morin; H Gautier
Journal:  Recent Results Cancer Res       Date:  1978

3.  Correlation of experimental and clinical studies of metabolism by PET scanning.

Authors:  P L Kornblith; C J Cummins; B H Smith; R A Brooks; N J Patronas; G Di Chiro
Journal:  Prog Exp Tumor Res       Date:  1984

4.  Preliminary results in some tumor systems with indazolecarboxylic acids.

Authors:  A Caputo
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

5.  Phase I toxicologic study of Lonidamine in cancer patients.

Authors:  P R Band; M Deschamps; J G Besner; R Leclaire; P Gervais; A De Sanctis
Journal:  Oncology       Date:  1984       Impact factor: 2.935

6.  Early observations on the administration of Lonidamine in cancer patients.

Authors:  A Barduagni; M Barduagni; L Di Lauro; M Nardi; C Gallo Curcio; R Tonachella; G B Ciottoli; S Delle Chiaie
Journal:  Oncology       Date:  1984       Impact factor: 2.935

7.  Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.

Authors:  C W Young; V E Currie; J H Kim; M A O'Hehir; F M Farag; J E Kinahan
Journal:  Oncology       Date:  1984       Impact factor: 2.935

8.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02

9.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.

Authors:  A Floridi; M G Paggi; S D'Atri; C De Martino; M L Marcante; B Silvestrini; A Caputo
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Inhibition of the recovery from potentially lethal damage by lonidamine.

Authors:  G M Hahn; I van Kersen; B Silvestrini
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640
View more
  6 in total

1.  Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance.

Authors:  Lige Leng; Ziqi Yuan; Ruiyuan Pan; Xiao Su; Han Wang; Jin Xue; Kai Zhuang; Ju Gao; Zhenlei Chen; Hui Lin; Wenting Xie; Huifang Li; Zhenyi Chen; Keke Ren; Xiao Zhang; Wenting Wang; Zi-Bing Jin; Shengxi Wu; Xinglong Wang; Zengqiang Yuan; Huaxi Xu; Hei-Man Chow; Jie Zhang
Journal:  Nat Metab       Date:  2022-10-06

Review 2.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.

Authors:  T Coyle; S Levante; M Shetler; J Winfield
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme.

Authors:  Stéphane Oudard; Antoine Carpentier; Eugeniu Banu; François Fauchon; Denis Celerier; Marie F Poupon; Bernard Dutrillaux; Jean M Andrieu; Jean Y Delattre
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

5.  Effect of lonidamine on human malignant gliomas: biochemical studies.

Authors:  M G Paggi; C M Carapella; M Fanciulli; C Del Carlo; S Giorno; G Zupi; B Silvestrini; A Caputo; A Floridi
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

Review 6.  GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.

Authors:  Alenoush Vartanian; Sanjay K Singh; Sameer Agnihotri; Shahrzad Jalali; Kelly Burrell; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2014-03-18       Impact factor: 12.300
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.